Single-subject experiments to determine individually differential effects of anxiolytics in generalized anxiety disorder

Neuropsychobiology

Volumn 33, Issue 4, 1996, Pages 196-201

  Wurthmann, C ^a   Klieser, E ^b   Lehmann, E ^c   Krauth, J ^c  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b University Hospital   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Generalized anxiety disorder; Pharmacotherapy; Single subject experiments

Indexed keywords

AMITRIPTYLINE; ANXIOLYTIC AGENT; CLOTIAZEPAM; FLUPENTIXOL;

ADULT; AGED; ANXIETY; ANXIETY NEUROSIS; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HYPOTHESIS; MALE; META ANALYSIS; PRIORITY JOURNAL;

ADULT; AMITRIPTYLINE; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 0029957067     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119277     Document Type: Article

References (37)

1. Brawmann-Mintzcr O, Lydiard B, Emmanuel N, Payeur R, Johnson M, Roberts J, Jarrell M, Ballenger J: Psychiatric comorbidity in patients with generalized anxiety disorder, Am J Psychiatry 1993;150:1216-1218.
2. Brown TA, Barlow DH, Liebowitz MR: The empirical evidence of generalized anxiety disorder, ArnJ Psychiatry 1994;151:1272-1280.
3. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3, revised, Washington, American Psychiatric Association, 1987.
4. Wittchen HU, Zhao S, Kessler RC, Eaton WW: DSM-111-R generalized anxiety disorder in the National Comorbidity Survey, Arch Gen Psychiatry 1994;51:355-364.
5. Faravclli C, Guerinni Degi'Innocenti BG, Giardinclli L: Epidemiology of anxiety disorders in Florence, Acta Psychiatr Scand 1989; 79:308-312.
6. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS: Lifetime and 12-month prcva-lcnccof DSM-111-Rpsychiatric disorders in the United States, Arch Gen Psychiatry 1994:51: 8-19.
7. Schweizer E, Rickcls K: Pharmacotherapy of generalized anxiety: in Rapce, Barlow (eds): Chronic Anxiety, Generalized Anxiety Disorder and Mixed Anxiety-Depression, New York, Guilford, 1991, pp 104-108.
8. Kahn RJ, McNair DM, Frankenthalcr LM: Tricyclic treatment of generalized anxiety disorder, J Affect Disord 1987;13:145-151.
9. Heinrich K, Lehmann E, Tegclcr J, Wurth-mann C: Fundamentals and results of controlled studies in ncuroleptanxiolysis; in Ste-fanis, Rabavilas, Soldatos (eds): Psychiatry, a World Perspective, Amsterdam, Elsevier, 1990, pp 248-253.
10. Wurthmann C, Klieser E: Treatment of anxiety disorders, Fortschr Neurol Psychiatr 1992:60: 91-103.
11. Wurthmann C, Klieser E, Lehmann E: Test therapy in the treatment of generalized anxiety disorders with low dose fiuspirilene, Prog Neuropsycho pharmacol Biol Psychiatry 1995; 19: 1049-1060.
12. Rickcls K, Downing R, Schweizer E, Hassman H: Antidepressants for the treatment of generalized anxiety disorder, Arch Gen Psychiatry 1993:50:884-895.
13. Edgington ES: Randomized single-subject experiments and statistical tests, J Couns Psychol 1987;34:437-442.
14. Krauth J: Experimental design and data analysis in behavioral pharmacology: in Haaren (ed): Methods in Behavioral Pharmacology, Amsterdam, Elsevier, 1993, pp 623-650.
15. Hamilton M: The assessment of anxiety states by rating, Br J Med Psychol 1959:32:50-55.
16. Edgington ES: Random assignment and statistical tests for one-subject experiments, Behav Assess 1980;2:19-28.
17. Margraf J, Schneider S, Ehlers A: DIPS - Diagnostisches Interview bei psychischen Störungen, Berlin, Springer, 1991.
18. Greene R: The MMP1, An Interpretive Manual, Orlando, Grune & Stratton, 1980.
19. Lehrl S: Mchrfachwahl-Wortschatz-Intelli-genztest MWT-B, Erlangen, Straube, 1977.
20. Binz U, Wendt G: Kurz-Skala Stimmung/Aktivierung, Frankfurt, Ciba-Gcigy, 1983.
21. National Institute Of Mental Health: Clinical Global Impressions; in Guy (ed): Assessment Manual for Psychopharmacology, Rockville, 1976, pp 217-222.
22. Edgington ES: An additive method for combining probability values from independent experiments, J Psychol 1972:80:351-363.
23. Bjerrum H, Allenip P, Thunedborg K, Jakob-sen K, Bcch P: Treatment of generalized anxiety disorder: Comparison of a new beta-blocking drug (CGP 361 A), low-dose neuroleptic (flupenthixol), and placebo, Pharmacopsychiatry 1992;25:229-232.
24. Ovhed I: A double-blind study of flupenthixol in general practice, Curr Med ResOpin 1976:4: 144-151.
25. Predescu V, Ciurczu T, Timoltc G, Roman I: Symptomatic relief with flupenlixol of the anxious-algetic-depressive syndrome complex in neurotic states, Acta Psychiatr Scand 1973:49: 15-27.
26. Wurthmann C, Klieser E, Lehmann E: Interaction of therapeutic effects and side effects in pharmacotherapy of generalized anxiety disorders with low-dosage lluspirilene, Fortschr Neurol Psychiatr 1995;63:72-77.
27. Kahn RJ, McNair DM, Lipman RS, Covi L, Rickcls K, Downing R, Fisher S, Frankenthaler LM: Imipramine and chlordiazcpoxide in depressive and anxiety disorders, Arch Gen Psychiatry 1986:43:79-85.
28. Diamond S: Double-blind controlled study of amitriptyline-perphenazine combination in medical office patients with depression and anxiety, Psychosomatics 1966;7:371-375.
29. Johnstone EC, Cunningham-Owcns DG, Frith CD, McPherson K, Dowie C, Riley G, Gold A: Neurotic illness and its response to anxiolytic and anti depressant treatment, Psychol Med 1980:10:321-328.
30. Rickels K, Csanalosi I, Chung HR, Case WG, Pereira-Ogan JA, Downing RW: Amitriptyline in anxious-depressed outpatients: A controlled study, Am J Psychiatry 1974; 131:25-30.
31. Splitter SR: Combined therapy with a new drug, Elavil (amitriptyline) and Trilafon (perphenazine) in a medical office setting, Psychosomatics 1965:6:322-326.
32. Wallerstcin E, Dykyj R, Nodinc JH: Fluphenazine and amitriptyline in the anxious depressed patient, Am J Psychiatry 1967; 124: 397-398.
33. Downing RW, Rickels K: Early treatment response in anxious outpatients treated with diazepam, Acta Psychiatr Scand 1985:72:522-528.
34. Namiki M, Kawakami K, Hasegawa N, Suzuki Z, Higuchi M, Ueno K, Nakano S, Tanaka M, Uemura NG, Ogawa N: A double-blind controlled study of the thienodiazepine derivate (Y-6047) on neurotics and psychosomatic disorders, J Jpn Psychosom Soc 1974:14:230-244.
35. Klicscr E, Lehmann E: Are there any predictors for a good response to placebo therapy? Pharmacopsychiatry 1989:22:201.
36. Detiege JJ, Lint J, van Dermaux P, Werli JJ, Steiner P: Anxiolytic versus antideprcssant as a first choice treatment in mixed anxiety and depression, Acta Ther 1987; 13:609-628.
37. Hoehn-Saric R, McLeod DR: Generalized anxiety disorder, Psychiatr Clin North Am 1985:8: 73-88.